TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis
Gilead and Galapagos Announce Tortuga Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint
pharmaceutical investing BioCryst Announces Publication of APeX-1 Clinical Trial Results for BCX7353 in The New England Journal of Medicine
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements
